{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:50:57Z","timestamp":1789775457150,"version":"4.0.1"},"reference-count":21,"publisher":"European Centre for Disease Control and Prevention (ECDC)","issue":"30","license":[{"start":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T00:00:00Z","timestamp":1406764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,31]]},"abstract":"<jats:p>We describe four cases in Sweden of verified treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg; n=3) or cefotaxime (500 mg; n=1) monotherapy. All the ceftriaxone treatment failures were caused by the internationally spreading multidrug-resistant gonococcal NG-MAST genogroup 1407 clone. Increased awareness of treatment failures is crucial particularly when antimicrobial monotherapy is used. Frequent test of cure and appropriate verification\/falsification of suspected treatment failures, as well as implementation of recommended dual antimicrobial therapy are imperative.<\/jats:p>","DOI":"10.2807\/1560-7917.es2014.19.30.20862","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T03:30:41Z","timestamp":1406863841000},"update-policy":"https:\/\/doi.org\/10.2807\/1560-7917.es.crp2020","source":"Crossref","is-referenced-by-count":53,"title":["Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014"],"prefix":"10.2807","volume":"19","author":[{"given":"D","family":"Golparian","sequence":"first","affiliation":[{"name":"World Health Organization Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections,   Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Ohlsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Janson","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Central Hospital, V\u00e4xj\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Lidbrink","sequence":"additional","affiliation":[{"name":"Department of Dermatovenereology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Richtner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Karolinska Institutet at S\u00f6dersjukhuset, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Ekelund","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Central Hospital, V\u00e4xj\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Fredlund","sequence":"additional","affiliation":[{"name":"World Health Organization Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections,   Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Unemo","sequence":"additional","affiliation":[{"name":"World Health Organization Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections,   Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7995","reference":[{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref01","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00010-14"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref02","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.63"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref03","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.042648"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref04","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.117"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref05","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.176575"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref06","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt034"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref07","doi-asserted-by":"publisher","DOI":"10.1071\/SH13077"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref08","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt017"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref09","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05760-11"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00325-11"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks162"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref12","doi-asserted-by":"publisher","DOI":"10.1086\/383047"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref13","doi-asserted-by":"crossref","unstructured":"Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA, et al. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Euro Surveill. 2013;18(3):pii=20358.","DOI":"10.2807\/ese.18.03.20358-en"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref14","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0. Basel: European Society of Clinical Microbiology and Infectious Diseases; 1 Jan 2014. Available from: http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Breakpoint_table_v_4.0.pdf"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00304-09"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref16","unstructured":"Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012;61(31):590-4."},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref17","doi-asserted-by":"publisher","DOI":"10.1177\/0956462412472837"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199501000-00007"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq289"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref20","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2012-050913"},{"key":"10.2807\/1560-7917.ES2014.19.30.20862_ref21","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.044586"}],"container-title":["Eurosurveillance"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T06:52:16Z","timestamp":1663224736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurosurveillance.org\/content\/10.2807\/1560-7917.ES2014.19.30.20862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,31]]},"references-count":21,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2014,7,31]]}},"URL":"https:\/\/doi.org\/10.2807\/1560-7917.es2014.19.30.20862","relation":{},"ISSN":["1560-7917"],"issn-type":[{"value":"1560-7917","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7,31]]}}}